Biosimilars in the US Cost 2.74 Times More Than in Other...
Germany, and Switzerland was bevacizumab, adalimumab, and rituximab, respectively. Comparatively, the lowest uptake was for products with infliximab, insulin lispro, and insulin glargine as the active ingredients.